COVID-19: Moderna Begins 3rd-Phase Trials, Eyes Year-End Vaccine Launch
New Delhi: Around 160 vaccines currently are being developed for COVID-19, and 25 of these are in human trial phases, according to the World Health Organization (WHO). These include Zydus and Bharat Biotech from India. Globally, leading the race are Moderna Inc and Oxford-AstraZeneca vaccines.
Moderna on Monday started phase-III human trials in the US. The earlier mover has completed phase-I and phase-II trials and is currently testing the vaccine on 30,000 volunteers. The mRNA-1273 vaccine will be given in two shots, 28 days apart.
The phase III will test the effectiveness of the vaccine. Technically, phase III will be completed in October 2022. However, considering the current pandemic situation, it will be simultaneously launched commercially depending on the preliminary data, sources said.